Propulsid Physician Education On Cardiac Risk To Be Presented To Committee

Janssen will detail professional education campaign plans for conveying cardiac risks associated with the nighttime heartburn treatment Propulsid (cisapride) at the April 12 FDA advisory committee review of the product's safety.